Comparing Safety and Efficacy of Rituximab and Eculizumab in Treating Refractory Myasthenia Gravis: A Systematic Review

Authors

  • Vineet Suryadevara
  • Yaman Habab
  • Alana Hutcheson
  • Binay Panjiyar
  • Gershon Davydov
  • Hiba Nashat
  • Sally Ghali
  • Shadin Afifi
  • Safeera Khan

DOI:

https://doi.org/10.56570/jimgs.v2i2.138

Keywords:

Myasthenia Gravis, Refractory Myasthenia Gravis, Rituximab, Eculizumab, Neuromuscular disease, Monoclonal antibodies

Abstract

Myasthenia gravis is a common
autoimmune disease in which patients experience
weakness primarily in the ocular, respiratory, bulbar,
and limb muscles. Although the symptoms of most
patients with myasthenia gravis are well controlled with
conventional immunotherapies, about 15% of them
experience a refractory disease. This systematic review
will focus on the safety and efficacy of monoclonal
antibodies, specifically rituximab and eculizumab, in
treating myasthenia gravis

Downloads

Published

2023-09-26

Issue

Vol. 2 No. 2 (2023): Vol. 2 No. 2 (2023)

Section

Articles